Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer

Ekaterina Mostovenko, Yanhong Liu, E. Susan Amirian, Spiridon Tsavachidis, Georgina N. Armstrong, Melissa L. Bondy, Carol L. Nilsson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.

Original languageEnglish (US)
Pages (from-to)80-84
Number of pages5
JournalACS Chemical Neuroscience
Volume9
Issue number1
DOIs
StatePublished - Jan 17 2018
Externally publishedYes

Fingerprint

Molecular Epidemiology
Brain Neoplasms
Glioma
Proteomics
Tumors
Brain
Glioblastoma
Neoplasms
Workflow
Pathology
Proteome
Standard of Care
Proteins
Therapeutics

Keywords

  • drug target
  • GBM
  • Glioblastoma
  • molecular epidemiology
  • precision medicine
  • proteomic

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Mostovenko, E., Liu, Y., Amirian, E. S., Tsavachidis, S., Armstrong, G. N., Bondy, M. L., & Nilsson, C. L. (2018). Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer. ACS Chemical Neuroscience, 9(1), 80-84. https://doi.org/10.1021/acschemneuro.7b00165

Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer. / Mostovenko, Ekaterina; Liu, Yanhong; Amirian, E. Susan; Tsavachidis, Spiridon; Armstrong, Georgina N.; Bondy, Melissa L.; Nilsson, Carol L.

In: ACS Chemical Neuroscience, Vol. 9, No. 1, 17.01.2018, p. 80-84.

Research output: Contribution to journalArticle

Mostovenko, E, Liu, Y, Amirian, ES, Tsavachidis, S, Armstrong, GN, Bondy, ML & Nilsson, CL 2018, 'Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer', ACS Chemical Neuroscience, vol. 9, no. 1, pp. 80-84. https://doi.org/10.1021/acschemneuro.7b00165
Mostovenko, Ekaterina ; Liu, Yanhong ; Amirian, E. Susan ; Tsavachidis, Spiridon ; Armstrong, Georgina N. ; Bondy, Melissa L. ; Nilsson, Carol L. / Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer. In: ACS Chemical Neuroscience. 2018 ; Vol. 9, No. 1. pp. 80-84.
@article{831ab627dcc04e43bd07346fba77d326,
title = "Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer",
abstract = "Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.",
keywords = "drug target, GBM, Glioblastoma, molecular epidemiology, precision medicine, proteomic",
author = "Ekaterina Mostovenko and Yanhong Liu and Amirian, {E. Susan} and Spiridon Tsavachidis and Armstrong, {Georgina N.} and Bondy, {Melissa L.} and Nilsson, {Carol L.}",
year = "2018",
month = "1",
day = "17",
doi = "10.1021/acschemneuro.7b00165",
language = "English (US)",
volume = "9",
pages = "80--84",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer

AU - Mostovenko, Ekaterina

AU - Liu, Yanhong

AU - Amirian, E. Susan

AU - Tsavachidis, Spiridon

AU - Armstrong, Georgina N.

AU - Bondy, Melissa L.

AU - Nilsson, Carol L.

PY - 2018/1/17

Y1 - 2018/1/17

N2 - Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.

AB - Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.

KW - drug target

KW - GBM

KW - Glioblastoma

KW - molecular epidemiology

KW - precision medicine

KW - proteomic

UR - http://www.scopus.com/inward/record.url?scp=85040670652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040670652&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.7b00165

DO - 10.1021/acschemneuro.7b00165

M3 - Article

VL - 9

SP - 80

EP - 84

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 1

ER -